PFA
NVO

Pathway Financial Advisers’s Novo Nordisk NVO Stock Holding History

Pathway Financial Advisers’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15
Closed -$1.84K – 440
2024
Q3 		$1.84K Sell
15
-252
-94% -$33.6K ﹤0.01% 355
2024
Q2 		$38K Buy
267
+1
+0.4% +$133 0.01% 246
2024
Q1 		$34.2K Buy
266
+15
+6% +$1.79K 0.01% 255
2023
Q4 		$25.9K Hold
251
– – 0.01% 278
2023
Q3 		$22.8K Buy
+251
New +$22.1K 0.01% 282

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.6B AUM 20.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Pathway Financial Advisers's NVO Position: Q4 2024 in Review

Pathway Financial Advisers sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 15 shares — an estimated $1.84K sold.

Pathway Financial Advisers first reported a position in NVO in Q3 2023 and held it in 5 quarters. The position peaked at $38K in Q2 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Pathway Financial Advisers reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Pathway Financial Advisers sold 15 Novo Nordisk shares in Q4 2024, an estimated $1.84K.
  • Pathway Financial Advisers first reported a position in Novo Nordisk in Q3 2023 and held it in 5 quarters.
  • Pathway Financial Advisers's Novo Nordisk position peaked at $38K in Q2 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Pathway Financial Advisers's 13F filing for Q4 2024, filed 30 Jan 2025.